{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-004155","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.018468+00:00","generated_at":"2026-06-06T02:10:48.149508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%","bullets":["Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.","ADHD Portfolio revenue jumped 49% to $16.6M; Rx Segment gross margin improved to 78% from 72%.","Operating income $2.4M vs. operating loss of $6.9M a year ago; net loss narrowed to $0.2M from $6.7M.","Adjusted EBITDA $5.1M (up 599% YoY); cash $19.5M at Dec 31, 2023.","Company winding down Consumer Health Segment to focus on Rx Segment; expects neutral segment EBITDA for FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-004155","json":"https://secwatch.observer/filing/0001437749-24-004155.json","markdown":"https://secwatch.observer/filing/0001437749-24-004155.md","text":"https://secwatch.observer/filing/0001437749-24-004155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/0001437749-24-004155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/aytu20240109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:10:48.149508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a482c4580502aa3b3b1e42072921826d67ea8bb","claim":"AYTU BIOPHARMA, INC reported fiscal 2024 second quarter results: revenue $22.9 million, net income $0.2 million, or $0.04 per share, EPS $0.04 per share.","evidence_excerpt":"on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter. ​ Q2 2024 Highlights ● Consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company's Consumer Health Segment. ● ADHD Portfolio (Adzenys","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/0001437749-24-004155-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 second quarter"},{"label":"Revenue","value":"$22.9 million"},{"label":"Net income","value":"$0.2 million, or $0.04 per share"},{"label":"EPS","value":"$0.04 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}